FIELD: medicine.
SUBSTANCE: invention relates to living attenuated recombinant influenza virus strains expressing earlier secretory antigen Mycobacteriun tuberculosis ESAT-6. Invention is useful in tuberculosis treatment and prophylaxis.
EFFECT: recombinant influenza virus vector with increased protective effect.
7 cl, 14 dwg, 11 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
RECOMBINANT STRAIN OF INFLUENZA VIRUS A/PR8-NS124-TB10_4-2A-HSPX AND METHOD FOR SPECIFIC PREVENTION OF PULMONARY TUBERCULOSIS USING MUCOSAL VACCINE BASED THEREON | 2019 |
|
RU2726106C1 |
RECOMBINANT INFLUENZA VIRUS STRAIN A/PR8/HK-NS80E85A, EXPRESSING FRAGMENTS OF ESAT-6 AND AG85A MYCOBACTERIUM TUBERCULOSIS ANTIGENS, TO OBTAIN TUBERCULOSIS VECTORED VACCINE | 2018 |
|
RU2678175C1 |
RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
VACCINE AGAINST TUBERCULOSIS | 2017 |
|
RU2647831C1 |
UNIVERSAL AVIAN INFLUENZA VIRUS VACCINE | 2007 |
|
RU2358981C2 |
ATTENUATED INFLUENZA VECTORS FOR THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES, AS WELL AS FOR CANCER TREATMENT | 2015 |
|
RU2628690C2 |
RECOMBINANT ANTI-INFLUENZA VACCINE WITH WIDE RANGE OF PROTECTION AND METHOD FOR ITS PREPARATION | 2017 |
|
RU2757013C2 |
ANTITUBERCULOUS VACCINE | 2007 |
|
RU2443773C2 |
VACCINE COMPOSITION FOR USE IN IMMUNO-COMPROMISED POPULATIONS | 2013 |
|
RU2661408C2 |
ANTI-FLU NANOANTIBODY, RECOMBINANT VIRAL VECTORS AND PHARMACEUTICAL COMPOSITIONS FOR PROPHYLAXIS AND THERAPY OF A-TYPE FLU | 2011 |
|
RU2502745C2 |
Authors
Dates
2008-03-10—Published
2005-09-16—Filed